CompletedNCT00646581
Single-dose insulin for memory and attention in schizophrenia
About this title
Read the official source — NCT00646581Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- University of Massachusetts, Worcester
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00646581
- Official title
Show the full official title
Effect of Single Dose Intranasal Insulin on Cognitive Function in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Massachusetts, Worcester, a university.
Did this study involve medication?
Yes. The study involved medication, including Placebo and Insulin (Humulin).
Who was this study for?
Listed age limits: 18 years to 65 years.
